Between the Biotech Waves

Nessan Bermingham PhD
  • 4.9 (21)
  • LIFE SCIENCES
  • UPDATED BIWEEKLY
Between the Biotech Waves

Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.

  1. 5 DAYS AGO

    S2 E3: A Between The Biotech Waves Conversation with Stan Crooke, Ionis & N-Lorem Founder

    In today's episode, I am honored to welcome Stanley Crooke, the founder and CEO of Ionis Pharmaceuticals the first and leading antisense oligonucleotide biotech and founder, CEO and Chair of N-Lorem, a not for profit entity developing ASOs for ultra rare diseases. Stan is THE pioneer in the field of antisense oligonucleotide based RNA-targeted therapies. With a deep passion for science and innovation, Stan has dedicated his career to transforming the landscape of drug discovery and developmen...

    1h 5m

  2. JAN 31

    S2 E2: A Between the Biotech Waves Conversation with Peter Barrett

    Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Barrett. Peter is a partner at Atlas Venture, where he has been a key player in the creation of numerous novel therapeutic and drug discovery platform companies. With an unyielding passion for advancing healthcare, Peter has been directly involved in co-fo...

    54 min

  3. JAN 24

    S2 Episode 1: A conversation with Matt Porteus

    Now that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting! Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the remarkable individuals driving innovation. I’m your host, Nessan Bermingham, and today, we are honored to have Dr. Matt Porteus with us, a true pioneer in the field of genome editing. Dr. Porteus is making headlines for his role in the development of Lyfgenia, the groundbreaking ...

    55 min

  4. 07/02/2024

    Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis

    Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go! Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of wo...

    1h 5m

  5. 07/19/2023

    Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics

    Today I am talking to Eliot Forster xCEO of F-star Therapeutics. Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS. Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pharmaceuticals following his multiple roles at Pfizer which included head of development and operations, European...

    1h 5m

  6. 07/19/2023

    Episode 32: The Triplet Therapeutics story, from concept to birth, life & death.

    Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building the company and what ultimately led to it's demise.

    1h 46m

  7. 07/02/2023

    Episode 31: A Between the Biotech Waves Conversation with Tim Yu

    Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Julia Vitarello to develop Milasen leading the way in truly personalized therapeutics. Please join me in welcoming Tim...

    56 min

  8. 07/02/2023

    Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics

    Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research an...

    46 min
See All (37)

Ratings & Reviews

4.9
out of 5
21 Ratings

About

Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.

Information

  • Creator
    Nessan Bermingham PhD
  • Years Active
    2022 - 2025
  • Episodes
    37
  • Rating
    Clean
  • Copyright
    © 2025 Between the Biotech Waves
  • Show Website
    Between the Biotech Waves

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada